Health Care Equipment

HAIER BIOMEDICAL

Haier Biomedical released FY2026 Q1 earnings on April 29 After-Market BJT, actual revenue CNY 652.08 M, actual EPS CNY 0.25

Haier Biomedical to Release FY2026 Q1 Earnings on April 30 After-Market (BJT)

Haier Biomedical to release FY2025 earnings on March 28, pre-market (BJT), forecast revenue CNY 2.628 B, EPS CNY 1.385

Haier Biomedical released FY2025 Q4 earnings on February 27 Pre-Market (BJT), actual revenue CNY 567.48 M, actual EPS CNY 0.1694

Haier Biomedical released FY2025 earnings on February 27 Pre-Market (BJT), actual revenue CNY 2.329 B (forecast CNY 2.628 B), actual EPS CNY 0.8 (forecast CNY 1.385)

Haier Biomedical released FY2025 9 Months earnings on October 30 After-Market (BJT), actual revenue CNY 1.761 B, actual EPS CNY 0.631

HAIER BIOMEDICAL released FY2025 Q3 earnings on October 30 After-Market (BJT), actual revenue CNY 565.69 M, actual EPS CNY 0.1793

Haier Biomedical FY2025 Q3 Earnings Release on October 31, 2025, After-Market (BJT)

Haier Biomedical released FY2025 Semi-Annual Earnings on August 26 After-Market (BJT), actual revenue CNY 1.196 B, actual EPS CNY 0.45

HAIER BIOMEDICAL released FY2025 Q2 earnings on August 26 After-Market (BJT), actual revenue CNY 506.51 M, actual EPS CNY 0.1017

Haier Biomedical to Release FY2025 Semi-Annual Earnings on August 27, 2025 (BJT)

Haier Bio-Tech Registers Vaccine Workstation Big Data Platform Software Copyright

Haier Bio-Repurcahsing Shares for Equity Incentives

Haier Bio-Medical Q1 2025 Revenue Up 0.30%, Net Profit Down 19.88%

HAIER BIOMEDICAL released FY2025 Q1 earnings on April 29 After-Market (BJT), actual revenue CNY 688.99 M, actual EPS CNY 0.35

Haier Biomedical FY2025 Q1 Earnings Release on April 30 After-Market BJT

Haier Biomedical Announces Haichuangzhi Increased Holdings by 5.7293 Million Shares

Haier Biomedical to Release FY2024 Earnings on March 29 After-Market (BJT), Forecast Revenue 2.572 B CNY, EPS 1.58 CNY

Haier Biomedical Deploys DeepSeek in Vaccine Appointment System and Smart Medication Scenarios

Haier Biomedical Collaborates with Multiple Hospitals in Shanghai on Smart Healthcare Projects

688139

Haier Biomedicalhas released its 2025 Sustainability Report, highlighting its commitment to environmental, social, and governance (ESG) progress. The report outlines the company's initiatives to enhance global health access through innovative, carbon-reducing technologies. Key achievements include a 50% increase in new patents and significant investments in R&D. The company integrates AI in product development, improving safety and efficiency in healthcare. Haier Biomedical aims to enhance patient well-being globally while supporting communities through donations totaling 1.4 million Yuan.

prnewswire

14:34 ETHaier Biomedical veröffentlicht den Nachhaltigkeitsbericht 2025: Engagement für den Aufbau einer Plattform für Technologie, Industrie und soziale Verantwortung

Haier Biomedical has published its 2025 Sustainability Report, highlighting its commitment to environmental, social, and governance goals. The report details advancements in R&D, with 28.56% of its workforce dedicated to innovation and significant investments in technology. The company integrates AI into healthcare solutions, enhancing safety and efficiency. Haier Biomedical also emphasizes digital quality management and sustainable practices, achieving numerous energy-saving certifications. The firm collaborates with global organizations to improve health equity and has made substantial contributions to public welfare.

PR Newswire

Haier Biomedical Publishes 2025 Sustainability Report: Committed to Building a Platform for Technology, Industry and Social Responsibility

Haier Biomedical (688139. SH) has reported a record 36% of its total revenue from international business, amounting to 840 million Yuan ($122.85 million) in 2025. The company achieved a total revenue of 2.33 billion Yuan ($340.77 million), with significant growth in overseas markets, particularly in the Asia-Pacific and Europe. Haier Biomedical is transitioning from product export to brand globalization, focusing on building a leading integrated platform for life-science tools. The company also announced strategic goals for the next three years, aiming for over 50% of revenue from international sales and over 30% from AI-related innovations.

17:53 ETHaier Biomedical treibt den globalen Fortschritt der Life-Science-Infrastruktur voran: Das internationale Geschäft erreicht 2025 einen Rekordanteil von 36 % am Jahresumsatz

At the analytica 2026 event in Munich on April 10, 2026, Haier Biomedical showcased its comprehensive laboratory solutions with a focus on serving Europe. As a prominent player in life sciences and medical technology, the company highlighted its offerings tailored to the European market.

Unusual Whales

"In Europe, For Europe": Haier Biomedical Spotlights Full-Scenario Lab Solutions at analytica Munich 2026

HAIER BIOMEDICAL(688139.SH)

14:34 ETHaier Biomedical veröffentlicht den Nachhaltigkeitsbericht 2025: Engagement für den Aufbau einer Plattform für Technologie, Industrie und soziale Verantwortung

Haier Biomedical Publishes 2025 Sustainability Report: Committed to Building a Platform for Technology, Industry and Social Responsibility

17:53 ETHaier Biomedical treibt den globalen Fortschritt der Life-Science-Infrastruktur voran: Das internationale Geschäft erreicht 2025 einen Rekordanteil von 36 % am Jahresumsatz

"In Europe, For Europe": Haier Biomedical Spotlights Full-Scenario Lab Solutions at analytica Munich 2026